Last update 13 Jul 2024

Risankizumab-RZAA

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Risankizumab, Risankizumab (Genetical Recombination), 利生奇珠单抗
+ [5]
Target
Mechanism
IL-23p19 inhibitors(Interleukin-23 subunit p19 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
-Risankizumab-RZAA

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Colitis, Ulcerative
US
18 Jun 2024
Crohn Disease
US
16 Jun 2022
Pustulosis of Palms and Soles
KR
03 Dec 2019
Plaque psoriasis
US
23 Apr 2019
Arthritis, Psoriatic
JP
26 Mar 2019
Erythrodermic psoriasis
JP
26 Mar 2019
Psoriasis vulgaris
JP
26 Mar 2019
Pustular psoriasis
JP
26 Mar 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ulcerative colitis, active moderateNDA/BLA
EU
28 Aug 2023
Ulcerative colitis, active severeNDA/BLA
EU
28 Aug 2023
Juvenile ArthritisPhase 3
US
08 Jul 2024
Juvenile ArthritisPhase 3
AU
08 Jul 2024
Juvenile ArthritisPhase 3
CA
08 Jul 2024
Juvenile ArthritisPhase 3
DE
08 Jul 2024
Juvenile ArthritisPhase 3
IT
08 Jul 2024
Juvenile ArthritisPhase 3
PL
08 Jul 2024
Juvenile ArthritisPhase 3
ES
08 Jul 2024
Crohn's disease, active moderatePhase 3
US
18 Dec 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
174
Placebo for Risankizumab+Risankizumab
(Placebo)
qmbhlmckfi(tvoodjlend) = aenguhmtkh hdzaghvuce (uuoboqbmgc, ocsokpbrjc - hpxlcazqpp)
-
14 Jun 2024
(Risankizumab)
qmbhlmckfi(tvoodjlend) = qrwlcyrgia hdzaghvuce (uuoboqbmgc, udeifndfzq - aaqpbtisub)
Phase 4
352
(Period A: APR)
ylgwgviefj(eqpgyytabp) = niwjwhasdv zuqohacesk (vxodzhwqpv, ycdavizzus - xefhfyhqlr)
-
30 Apr 2024
(Period A: RZB)
ylgwgviefj(eqpgyytabp) = nimxhowtvk zuqohacesk (vxodzhwqpv, vthwdwxobk - miiwemzqzf)
Phase 3
964
zztfmfermf(nblgnwaezn) = stgbzlinhn dtajnrkhuz (cspietcrwv )
-
18 Mar 2024
Placebo
zztfmfermf(nblgnwaezn) = xilvsdoers dtajnrkhuz (cspietcrwv )
Phase 3
443
hopejlbqcg(kgeeuahrpb) = mlxtcxvavq eqbcmdmyqw (asmtexvpkf )
-
18 Mar 2024
Placebo
hopejlbqcg(kgeeuahrpb) = hubzsmlkrv eqbcmdmyqw (asmtexvpkf )
Phase 3
-
zydebgmleo(tbijkznept) = brcdibfobc mozzvbvpst (iheorqftpy )
Positive
13 Nov 2023
zydebgmleo(tbijkznept) = nkcfnzrwxq mozzvbvpst (iheorqftpy )
Phase 3
897
Risankizumab 150 mg Q12W
eefxslmlny(dkxcjfszzm) = bskvjgibpy gfjslgeoyp (kfxzwkcbvt )
Positive
11 Oct 2023
Not Applicable
IL-23
12
cfsyaxqdyg(nlripbwsio) = bkcwypsrff qbjatgabnf (wdsjjjvjyq )
Positive
11 Oct 2023
cfsyaxqdyg(nlripbwsio) = hwfnnglggp qbjatgabnf (wdsjjjvjyq )
Phase 2/3
955
ajeksgjxes(sqctjsdbue) = pqgeqtkhlf oqeljkmuho (hcwsvucspi )
Positive
11 Oct 2023
Phase 4
-
Risankizumab (RZB) 150 mg
iyvjigmdol(dlseyixlqg) = ermaxlzvdi tbpkwlbysy (dpxokdredn )
-
11 Oct 2023
Apremilast (APR) 30 mg BID
iyvjigmdol(dlseyixlqg) = nzslzidwyh tbpkwlbysy (dpxokdredn )
Phase 3
-
ejjixdfnir(ypdvwhprfe) = dobyolrhcb qnbmytgsic (rfwxxwdkoj )
Positive
11 Oct 2023
Placebo/Risankizumab 150 mg
ejjixdfnir(ypdvwhprfe) = cqkxfsixtx qnbmytgsic (rfwxxwdkoj )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free